Celiac patients given FB102 kept more intestinal lining under gluten challenge, argenx reports

The case for CD122 starts in mice. In 2009, researchers showed that blocking the receptor in mice with gut autoimmune problems reversed intestinal damage ^[12]. From that work came the idea that CD122, and the way it interacts with inflammatory signals, is key to how celiac disease starts and keeps going ^[13]. Forte Biosciences, later acquired by argenx, developed FB102 to test it ^[14].

Luc Truyen, argenx's chief medical officer, framed the result around the lack of options. "These positive Phase 2 results strengthen our conviction in the potential of FB102 to address a significant unmet need for people living with celiac disease, where there are currently no approved therapies," he said ^[7]. argenx is not the only company in the field. ScienceAlert says several other pharmaceuticals are under investigation by drug companies ^[19].

ScienceAlert describes gluten damage in celiac disease as shortened projections on the intestinal wall and deeper grooves between them ^[15]. The fewer signs of that injury in treated patients come from a placebo comparison in which neither participants nor researchers knew who got FB102 ^[4]. In our view, that makes the lining result a credible signal at phase 2.

The thing this doesn't tell you is how the drug behaves outside the trial. ScienceAlert notes the drug was given under controlled conditions, that it is unclear whether the protection holds in a real-world setting, and that the result does not mean patients could eat gluten without care ^[8].

The regulatory bar is longer. According to ScienceAlert, the FDA's draft guidance says a chronically administered compound like FB102 would need to show efficacy for at least 52 weeks, and without a gluten challenge ^[9]. Against the trial's eight-week challenge ^[4], 52 weeks is 6.5 times as long ^[20]. The comparison is rough, since one figure is a trial duration in the guidance and the other is a challenge window here. ScienceAlert says researchers at argenx are still working up to that standard ^[18].

Truyen said the findings support the next step. "Combined with the consistent safety profile observed across studies," he said, "these findings support advancing FB102 into Phase 3 development and further exploring its broader potential across immune-mediated diseases" ^[17].